Key Takeaways
- St. Peter’s Health Partners (SPHP) has introduced a robotic catheter‑based bronchoscopy system to improve early detection of peripheral lung nodules.
- The technology combines CT‑derived 3‑D lung mapping with shape‑sensing fiber‑optic catheters, providing real‑time navigation to lesions previously inaccessible with conventional bronchoscopy.
- The first robotic bronchoscopies were performed on June 12 at Samaritan Hospital by Drs. Joseph Seguel, Hau Chieng, and Tracey Weigel.
- Compared with traditional CT‑guided lung biopsies, the robotic approach is faster, less invasive, and associated with fewer complications, supporting better quality of life.
- SPHP’s longstanding cancer‑care accreditation and affiliation with Roswell Park Comprehensive Cancer Center position the health system to deliver leading‑edge, integrated oncology services close to home.
Introduction
St. Peter’s Health Partners (SPHP), a recognized national leader in robotic surgery, is extending its expertise in minimally invasive techniques to the realm of lung‑cancer screening. Early detection remains the cornerstone of successful lung‑cancer treatment, yet the disease’s asymptomatic nature in its initial stages often delays diagnosis until curative options are limited. By acquiring a state‑of‑the‑art robotic catheter‑based bronchoscopy system, SPHP aims to bridge this gap, offering patients a more precise, less invasive pathway to identify and biopsy peripheral lung nodules—lesions that reside in the narrow, hard‑to‑reach airways of the outer lung.
Technology Overview
The newly acquired platform integrates three core components: high‑resolution CT imaging, sophisticated planning software, and a shape‑sensing ultrathin catheter. Prior to the procedure, a diagnostic CT scan is processed to generate a detailed three‑dimensional map of the patient’s bronchial tree, down to the smallest subsegmental branches and any suspicious nodules. The planning software then calculates an optimal trajectory from the trachea to the target lesion, avoiding vascular structures and minimizing airway trauma.
During the bronchoscopy, the physician advances a catheter embedded with a fiber‑optic sensor that records hundreds of positional measurements per second. This sensor feeds real‑time data back to the navigation console, displaying the catheter’s exact location, orientation, and shape within the airway lumen. The result is a dynamic, GPS‑like guidance system that allows the operator to steer the instrument with sub‑millimeter accuracy, reaching nodules that would be missed or inadequately sampled by standard flexible bronchoscopy or percutaneous CT‑guided needle biopsy.
Clinical Procedure and First Cases
On June 12, the SPHP team performed the health system’s inaugural robotic bronchoscopies at Samaritan Hospital. Dr. Joseph Seguel, director of advanced bronchoscopy, led the procedure alongside Dr. Hau Chieng of Pulmonary & Critical Care Services and Dr. Tracey Weigel of Albany Thoracic & Esophageal Surgery. The cases involved patients with indeterminate peripheral nodules identified on routine screening CTs. Using the robotic system, the clinicians navigated the catheter through complex airway branches, visualized the lesion in real time, obtained tissue samples, and completed the biopsy without the need for a percutaneous transthoracic approach.
Both physicians emphasized that the system’s ability to reach more than 70 % of cancerous nodules located in the peripheral lung—areas traditionally considered “blind spots”—represents a paradigm shift in diagnostic bronchoscopy. The procedural time was markedly shorter than that required for CT‑guided needle biopsies, and patients reported minimal discomfort during and after the intervention.
Benefits Over Traditional Methods
Traditional diagnostic pathways for peripheral lung lesions include CT‑guided transthoracic needle biopsy and conventional flexible bronchoscopy with fluoroscopic guidance. While effective, these methods carry notable drawbacks: transthoracic biopsies pose a higher risk of pneumothorax and bleeding, and conventional bronchoscopy often fails to reach distal lesions, leading to nondiagnostic results or the need for repeat procedures.
The robotic catheter system mitigates these limitations in several ways. First, the ultrathin catheter (typically <2 mm in diameter) can navigate tight airway spaces without causing significant mucosal trauma. Second, the continuous shape‑sensing feedback reduces reliance on intermittent fluoroscopy, lowering radiation exposure for both patient and staff. Third, the real‑time visualization enables targeted sampling, increasing diagnostic yield while decreasing the number of needle passes. Consequently, patients experience fewer complications, shorter recovery times, and a quicker path to definitive diagnosis—factors that collectively enhance quality of life and expedite initiation of therapy when malignancy is confirmed.
Impact on Patient Outcomes
Early-stage lung cancer, when detected before metastasis, offers the best chance for curative resection or targeted therapy, with five‑year survival rates exceeding 60 % in many series. By improving the sensitivity and safety of peripheral nodule biopsy, SPHP’s robotic bronchoscopy contributes directly to stage migration—shifting more diagnoses from advanced to early disease. Faster, less invasive diagnostics also reduce patient anxiety and healthcare utilization, as fewer repeat imaging studies or hospitalizations are required. Moreover, the ability to perform the procedure in an outpatient setting aligns with the broader trend toward ambulatory cancer care, decreasing costs and increasing accessibility for underserved populations within the SPHP service area.
SPHP’s Cancer Care Excellence
St. Peter’s Health Partners has long been a benchmark for comprehensive oncology services. Since 1985, its Cancer Care Center has held accreditation as a Comprehensive, Community‑based Cancer Care Program by the American College of Surgeons Commission on Cancer®. The program’s affiliation with Roswell Park Comprehensive Cancer Center further reinforces its commitment to evidence‑based, cutting‑edge treatment modalities.
The multidisciplinary tumor board—comprising medical oncologists, thoracic surgeons, pathologists, radiologists, pulmonologists, and genetic counselors—ensures that each patient receives a personalized, integrated plan spanning diagnosis, staging, therapy, and survivorship support. The addition of robotic bronchoscopy enriches this ecosystem by providing a minimally invasive diagnostic tool that seamlessly feeds into the existing pathways for surgical resection, stereotactic body radiotherapy, immunotherapy, and clinical trial enrollment.
Integration with Existing Services
SPHP’s Cancer Care Center operates across St. Peter’s and Samaritan hospitals, offering a full spectrum of services including advanced imaging (PET/CT, MRI), molecular pathology, genetic testing, and state‑of‑the‑art endoscopic interventions such as endoscopic ultrasound‑guided fine‑needle aspiration (EUS‑FNA) and navigational bronchoscopy for mediastinal staging. The robotic catheter platform complements these modalities by filling a specific diagnostic gap: peripheral lung nodules that are too small or too deep for conventional bronchoscopy yet pose a prohibitive risk for percutaneous approaches.
Through coordinated scheduling, the pulmonary and thoracic surgery teams can now offer a “one‑stop” diagnostic encounter: a screening CT, followed immediately (if indicated) by robotic bronchoscopy with on‑site pathology evaluation (rapid‑section cytology). This streamlined workflow reduces time from suspicion to diagnosis—a critical factor encapsulated by Dr. Nicholas Montalto’s assertion that “time matters” in lung cancer management.
Future Directions and Community Access
Looking ahead, SPHP envisions expanding the robotic bronchoscopy program to additional campuses within its network, thereby increasing geographic reach for patients who might otherwise travel to tertiary centers for advanced diagnostics. Ongoing training initiatives will certify more interventional pulmonologists and thoracic surgeons in the system’s use, fostering a culture of procedural excellence and safety.
Research collaborations are also being explored to evaluate the platform’s potential beyond biopsy—such as delivering localized therapeutic agents (e.g., chemotherapy, immunotherapy, or radio‑ablative technologies) directly to lung lesions, a concept known as “robotic bronchoscopic therapy.” Early-phase trials in other institutions have shown promise, and SPHP’s robust clinical trial infrastructure positions it to participate in or lead such investigations.
Conclusion
The acquisition of a robotic catheter‑based bronchoscopy system marks a significant advancement in St. Peter’s Health Partners’ fight against lung cancer. By enabling precise, minimally invasive access to peripheral lung nodules, the technology addresses a longstanding diagnostic challenge, improves patient safety, and accelerates the journey from detection to treatment. Coupled with SPHP’s esteemed cancer‑care pedigree, multidisciplinary expertise, and community‑focused mission, this innovation reinforces the health system’s role as a transforming healing presence—delivering leading‑edge, compassionate care closer to home for those at risk of or affected by lung cancer.